Pharmaceuticals

The appointment of drug development veteran Dr. Aaron Koenig at Syremis Therapeutics is more than a new hire; it's a strategic play in the high-stakes race to redefine mental health treatment.

Biotech firm ProJenX reports its novel ALS drug, prosetin, is safe and hits key targets in early trials, offering a new beacon of hope for the disease.

Acurx Pharma's new drug, ibezapolstat, offers a novel weapon against deadly infections like C. diff by sparing good bacteria. Is this the breakthrough we need?

Verge Labs' new AI model promises to predict brain activity from a blood draw, potentially upending the costly and failure-prone world of neurology R&D.

Tiny biotech HCW Biologics reports promising early data for its alopecia drug. But with a small sample size and big pharma rivals, is this a true breakthrough?

Pasithea Therapeutics is expanding its NF1 trial for PAS-004, a move that signals a deeper strategic commitment to outmaneuvering competitors and meeting a critical unmet medical need.

A new survey reveals an overwhelming public demand to treat epinephrine like defibrillators. This isn't just about allergies; it's a systemic shift in our definition of public safety.

As USANA marks 10 years of its World Service Week, a closer look reveals how its direct-selling network is strategically engineered to power a global charity.

Edgewise Therapeutics unveils strong Phase 2 data for its HCM drug, EDG-7500, showing efficacy without the cardiac risks plaguing market leaders.

A short-seller report alleges ADMA faked 20% growth, triggering a 40% stock collapse and a securities fraud lawsuit with an August 10 investor deadline.

With a major debt financing, French biotech Inventiva is funded through a pivotal Phase 3 trial for its MASH drug, highlighting a strategic shift in biotech funding.

As DuPont prepares to reveal a new Tyvek® for ASEAN, the focus shifts from mere compliance to integrating comfort, productivity, and holistic worker safety.

Faculty's new AI developer studio promises to cut drug trial planning from weeks to minutes, a major growth signal in the high-stakes life sciences race.

Enterprises are stuck between rapid AI prototyping and the slow, necessary grind of governance. Dataiku's new AI agent, Cobuild, promises to unite them.

A Chinese firm is expanding its role in the hidden, high-stakes supply chain for semiconductors and advanced manufacturing. Here’s why it matters.

Icelandic biotech Alvotech seeks $125M in a complex dual offering to advance its low-cost drug pipeline, but regulatory hurdles and financial pressures loom.

Verastem Oncology is preparing to show its hand with VS-7375, a novel dual-action KRAS G12D inhibitor. Can its unique science disrupt a crowded market?

HPE's new quantum strategy isn't just about qubits; it's about building a resilient bridge between classical HPC and the quantum future.

AIRA ushers in new leadership with Boris Steffen as President, poised to navigate economic turbulence and shape the future of the insolvency profession.

The FDA's approval of a new Type 1 Diabetes therapy is a landmark. But the real story is the collaborative engine clearing the path for future breakthroughs.